Silverback Therapeutics (SBTX) Competitors $13.44 -0.45 (-3.24%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SBTX vs. CALT, ZYME, MBX, AVTE, NLTX, BIOA, CYBN, VIRI, WHWK, and OSTXShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and OS Therapies (OSTX). Silverback Therapeutics vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Silverback Therapeutics (NASDAQ:SBTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Which has more volatility and risk, SBTX or CALT? Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Does the media prefer SBTX or CALT? In the previous week, Silverback Therapeutics' average media sentiment score of 1.16 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Silverback Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silverback Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral Do insiders and institutionals have more ownership in SBTX or CALT? 74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, SBTX or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Silverback Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-5.55Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Is SBTX or CALT more profitable? Silverback Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Silverback Therapeutics' return on equity of -29.62% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% SummarySilverback Therapeutics beats Calliditas Therapeutics AB (publ) on 6 of the 11 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$484.62M$851.80M$5.76B$9.84BDividend YieldN/A4.84%3.95%4.02%P/E Ratio-5.551.1531.3126.60Price / SalesN/A26.88461.30121.37Price / CashN/A19.5637.7659.36Price / Book1.816.7310.026.67Net Income-$89.48M-$4.20M$3.27B$265.59M7 Day Performance-7.95%15.29%3.17%3.42%1 Month Performance-24.79%16.58%4.34%1.09%1 Year Performance-3.72%33.25%44.11%23.85% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$13.44-3.2%N/A-0.5%$484.62MN/A-5.5583Positive NewsHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.3287 of 5 stars$14.10+0.4%$21.43+52.0%+29.0%$1.06B$122.87M-9.40460MBXMBX Biosciences2.5664 of 5 stars$13.43-7.8%$37.63+180.2%N/A$451.17MN/A-2.9636News CoverageAVTEAerovate TherapeuticsN/A$7.50+1.9%N/A-87.8%$217.39MN/A-2.5120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.51+1.5%N/A-44.4%$192.75MN/A-6.5990High Trading VolumeBIOABioAge LabsN/A$4.41-2.4%N/AN/A$158.10M$3.86M0.00N/ACYBNCybin2.3935 of 5 stars$6.61-4.5%$85.00+1,186.7%N/A$155.84MN/A-1.5150VIRIVirios TherapeuticsN/A$5.30+7.5%$5.00-5.7%+2,309.5%$102.07MN/A-19.635WHWKWhitehawk TherapeuticsN/A$1.65+2.5%N/AN/A$77.76M$25.98M-27.5040Positive NewsHigh Trading VolumeOSTXOS Therapies2.2037 of 5 stars$2.13-2.3%$18.00+745.1%-38.1%$67.36MN/A-2.48N/ANews CoverageAnalyst Forecast Related Companies and Tools Related Companies CALT Alternatives ZYME Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives BIOA Alternatives CYBN Alternatives VIRI Alternatives WHWK Alternatives OSTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access